TABLE 12Meta-analysis of adalimumab efficacy data: outcomes at 12 weeks

TrialOutcomesAdalimumabPlaceboRR or mean difference (95% CI)
PsARC
ADEPT51,88,92,93,100–10494/151 (62%)42/162 (26%)2.40 (1.80 to 3.20)
Genovese 20078326/51 (51%)14/49 (24%)1.78 (1.06 to 3.00)
Pooled RR (95% CI), p-value2.24 (1.74 to 2.88), p < 0.0001
I2I2 = 0%
ACR 20
ADEPT51,88,92,93,100–10488/151 (58%)23/162 (14%)4.10 (2.75 to 6.14)
Genovese 20078320/51 (39%)8/49 (16%)2.40 (1.17 to 4.94)
Pooled RR (95% CI), p-value3.65 (2.57,5.17), p < 0.0001
I2I2 = 38%
ACR 50
ADEPT51,88,92,93,100–10454/151 (36%)6/162 (4%)9.66 (4.28 to 21.79)
Genovese 20078313/51 (25%)1/49 (2%)12.49 (1.70 to 91.90)
Pooled RR (95% CI), p-value10.08 (4.74 to 21.44), p < 0.0001
I2I2 = 0%
ACR 70
ADEPT51,88,92,93,100–10430/151 (20%)1/162 (1%)32.19 (4.44 to 233.11)
Genovese 2007837/51 (14%)0/49 (0%)14.42 (0.85 to 5.26)
Pooled RR (95% CI), p-value26.05 (5.18 to 130.88), p < 0.0001
I2I2 = 0%
HAQ change from baseline [mean (SD)]
ADEPT51,88,92,93,100–104−0.4 (0.5)−0.1 (0.5)−0.3 (−0.41 to −0.19)
Genovese 200783−0.3 (0.5)−0.1 (0.3)−0.2 (−0.36 to −0.04), p = 0.015
Pooled WMD (95% CI), p-value−0.27 (−0.36, −0.18), p < 0.0001
I2I2 = 0.6%

WMD, weighted mean difference.

From: 3, Assessment of clinical effectiveness

Cover of Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation
Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.10.
Rodgers M, Epstein D, Bojke L, et al.
Southampton (UK): NIHR Journals Library; 2011 Feb.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.